報價延遲最少15分鐘:2026/04/25 15:48 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.13 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.37/0.22
|
|
企業價值
1.50B
|
| 資產負債 |
|
每股賬面淨值
0.06
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
9.68M
|
|
每股收益
0.06
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar. |
